Executive Summary

​

Tenosynovial Giant Cell Tumor (TGCT) remains one of the most frequently missed diagnoses in musculoskeletal care—not because it is rare, but because it presents like something common.

​

Patients often enter the healthcare system with joint pain, swelling, and functional limitations that closely resemble routine sports injuries. As a result, TGCT is frequently managed as a benign orthopedic condition for months or years before the correct diagnosis is made. Published evidence demonstrates a median diagnostic delay of 16.9 months, with many patients seeing multiple providers before reaching an accurate diagnosis .

​

These delays are not clinically trivial. TGCT, while technically benign, is locally aggressive and progressive. Over time, untreated disease can lead to joint damage, functional decline, and long-term quality-of-life impairment. As highlighted by clinical experts, delays can increase treatment complexity, requiring repeated surgeries or more advanced therapeutic strategies, while also compounding physical and emotional burden for often young, active patients .

​

The Missed Opportunity: Sports Medicine as the Front Line

Sports medicine clinicians are uniquely positioned at the earliest point of interception in the TGCT patient journey. They are often the first specialists to evaluate patients with persistent joint symptoms—yet TGCT is rarely top-of-mind.

​

As described by frontline clinicians, TGCT “blends seamlessly into the everyday sports injury landscape,” frequently mimicking meniscal injuries, cartilage damage, or overuse conditions. The default clinical mindset—“common things being common”—can delay consideration of less typical diagnoses.

​

However, key inflection points exist. Persistent symptoms beyond expected recovery timelines, discordance between history and presentation, and recurrent joint swelling are signals that should prompt reconsideration. Experts emphasize that when symptoms persist beyond 3–6 months, clinicians should “pause and step back” and consider diagnoses beyond routine injury, including TGCT .

​

Educational Solution: From Recognition to Action

CATCH-TGCT: Closing the Sports Medicine Diagnostic Gap is a targeted, implementation-focused educational initiative designed to shift TGCT from a missed diagnosis to a considered one.

​

The program centers on a three-episode expert-led podcast series, supported by an integrated microsite and practical diagnostic tools. Rather than focusing solely on disease knowledge, the initiative emphasizes:

• Pattern recognition in real-world clinical scenarios

• Clear triggers for imaging and referral

• Practical decision-making within time-constrained sports medicine workflows

• Interdisciplinary coordination between sports medicine, radiology, and orthopedic oncology

​

This approach reflects how clinicians actually learn and change practice—through stories, case-based insights, and visual pattern recognition, not abstract didactics.

​

From Awareness to Earlier Diagnosis

The ultimate goal of this initiative is simple but high impact: Move TGCT earlier in the diagnostic consideration set.

​

Not necessarily as the first diagnosis—but as one that is no longer overlooked.

​

By increasing awareness at the front line of care, the program aims to:

• Reduce unnecessary cycles of conservative treatment

• Prompt earlier use of appropriate imaging (e.g., MRI)

• Improve timing of specialist referral

• Decrease overall time to diagnosis

​

Anticipated Impact

This initiative targets 600–800 sports medicine clinicians, with measurable outcomes across knowledge, competence, and practice behavior, including:

• Improved recognition of TGCT in athletes and active patients

• Increased confidence in differentiating TGCT from common injuries

• Earlier imaging and referral patterns

• Reduced diagnostic delay and downstream patient burden

​

By addressing a clearly defined gap at a critical point in the care pathway, CATCH-TGCT represents a focused, scalable approach to improving diagnostic accuracy and patient outcomes in a disease where earlier recognition changes everything.

​

Closing Insight

Early diagnosis is the most underutilized lever in TGCT care. When clinicians begin to “think zebra alongside horse,” patients move more quickly from uncertainty to clarity—and from delayed care to appropriate management.

​

This initiative is designed to make that shift possible.